A single-center retrospective study to determine viral suppression and safety/tolerability profiles in people living with HIV and end-stage renal disease on hemodialysis after Antiretroviral therapy (fixed dose combination of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2021 New trial record
- 01 Sep 2021 Results published in the International Journal of STD and AIDS